With most major health systems using patient portals for scheduling COVID-19 vaccinations, many older adults may need help setting up accounts. This situation is considered especially true for those older people with lower incomes and education levels, according to data from the National Poll on Healthy Aging at the University of Michigan Institute for Healthcare Policy and Innovation.
I’ve written previously on Covering Health about the potential harms of reporting on surveys and polls about people’s intent to get the COVID-19 vaccine. In late September, the FDA had not yet authorized any vaccines, so any poll or survey questions were theoretical. Now that vaccines are in distribution, however, does that change things?
Journalists reporting on the rollout of the COVID-19 vaccine have a new tool to guide their coverage: a Vaccine Education Toolkit that includes survey results on audience attitudes and needs, B-roll and multimedia, webinars, recommended experts and tips on reaching specific audiences. This resource may be a helpful complement to the AHCJ’s extensive resources on reporting about the pandemic.
The bilingual website was developed by three groups: the National Association of Broadcasters (NAB), the Donald W. Reynolds Journalism Institute (RJI) and the National Association of Chain Drug Stores (NACDS). RJI is a part of the Missouri School of Journalism and the NACDS is an industry trade group representing traditional drug stores, supermarkets and mass merchants with pharmacies. Continue reading
While describing the efforts of the National Institutes of Health and its partnerships with other agencies and pharmaceutical companies, NIH Director Francis Collins described the endeavor as “the most amazing outpouring of scientific capabilities, determination, talent that I’ve ever seen in my 27 years at NIH.”
During a recorded keynote speech at AHCJ’s Journalism Summit on Infectious Disease on Nov. 18, Collins said “The news [about recently announced vaccine trials] is extremely good. Both of these involving trials of 30,000 or more participants have been able to show that the messenger RNA-based vaccine strategy has resulted in over 90% efficacy for both of these and what appears to be a very reasonable safety record as well.” Continue reading
The race for COVID-19 vaccines won’t be the last vaccine race we’ll see. Vaccines for HIV are in the pipeline, scientists continue to work toward the elusive universal flu vaccine, and novel viruses we haven’t yet seen are likely in our future.
But the race for a COVID-19 vaccine has been a sprint compared to the marathon style of past vaccine development.
What does that mean for journalists covering development of the COVID-19 vaccine? How does this process differ from past ones, and what lessons and technologies might be applied to future vaccine efforts? How will society react when future vaccines become available? Continue reading
Valerie Montgomery Rice, M.D., is afraid of needles. Nevertheless, she agreed to receive her coronavirus vaccine on national television last Friday, along with CNN’s Sanjay Gupta, M.D.
Rice, who is dean of Atlanta’s Morehouse School of Medicine, knows the history of racism in medical research and understands some Black Americans’ reluctance to get the vaccine. As CNN’s Nicquel Terry Ellis reported, Rice trusts the Pfizer-BioNTech vaccine and would not recommend it if she did not trust it. To emphasize the point, Rice noted that Black scientists and doctors played significant roles in developing the vaccine and reviewing Pfizer’s FDA application for approval. Continue reading